feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Cavaliers beat Pacers in NBA

trending

Anthony Edwards scores 41 points

trending

Mater Dei loses to Centennial

trending

Norris takes Vegas pole position

trending

William kisses Kate Middleton

trending

Abu Dhabi Games of Future

trending

China overtakes Germany trade

trending

Chris Robertson teacher educator dies

trending

iPhone 17 Pro Max revealed

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Cancer Breakthrough: Repurposed Worm Drug Excels

Cancer Breakthrough: Repurposed Worm Drug Excels

20 Nov

•

Summary

  • A 40-year-old anti-worm medication is showing promise in cancer treatment.
  • A new form, polymorph C, effectively targets tumors, including brain tumors.
  • This repurposed drug could accelerate clinical trials due to its safety profile.
Cancer Breakthrough: Repurposed Worm Drug Excels

A repurposed 40-year-old anti-worm medication is now at the forefront of a potential cancer treatment breakthrough. Researchers at Johns Hopkins University have patented a novel form of mebendazole, termed polymorph C, which exhibits superior efficacy against a wide range of cancers compared to existing versions.

This specific crystalline form, polymorph C, is engineered to penetrate tumors more effectively, notably reaching brain tumors that are typically inaccessible to most drugs due to the blood-brain barrier. Preclinical studies in mice have shown that this form achieves effective concentrations within tumors, leading to enhanced tumor suppression with acceptable toxicity.

The established safety record of mebendazole, having been in use for decades, offers a significant advantage, potentially expediting its progression into human clinical trials. This repurposing of a well-understood drug could provide an affordable and trusted new avenue for cancer therapy.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Mebendazole polymorph C is a newly patented crystalline form of an old anti-worm drug, developed by Johns Hopkins researchers to more effectively target and suppress cancer cells.
Yes, mebendazole polymorph C is designed to cross the blood-brain barrier, reaching brain tumors in effective concentrations for potential treatment.
Researchers found that a specific form of mebendazole, polymorph C, has potent anti-cancer properties and its existing safety profile could speed up clinical trials.

Read more news on

Healthside-arrow

You may also like

Mounjaro Jab May Curb Food Cravings by Altering Brain Signals, Study Finds

18 Nov • 17 reads

article image

Decades-Old Blood Pressure Pill Shows Promise in Fighting Deadly Brain Cancer

18 Nov • 13 reads

article image

Enlarged Pancreatic Ducts Linked to Higher Odds of Deadly Cancer

14 Nov • 85 reads

Pioneering Scientists Crack the Code of Autoimmune Diseases

13 Nov • 50 reads

article image

Novartis Unveils GanLum, a Next-Gen Anti-Malaria Drug Offering Hope Against Resistance

13 Nov • 53 reads